Published

May 11, 2025

Eribulin [ERIB1]

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens

  1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
  2. I confirm that the patient has advanced breast cancer
  3. I confirm that the patient has has at least 2 prior chemotherapy regimens for advanced disease
  4. I confirm the licensed dose and frequency of eribulin will be used.

NHS funded From: 21 December 2016

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA423 (21 December 2016)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.